IL318183A - Formulations and doses of pegylated uricase - Google Patents
Formulations and doses of pegylated uricaseInfo
- Publication number
- IL318183A IL318183A IL318183A IL31818325A IL318183A IL 318183 A IL318183 A IL 318183A IL 318183 A IL318183 A IL 318183A IL 31818325 A IL31818325 A IL 31818325A IL 318183 A IL318183 A IL 318183A
- Authority
- IL
- Israel
- Prior art keywords
- composition
- administered
- synthetic nanocarriers
- pegsiticase
- rapamycin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307412P | 2016-03-11 | 2016-03-11 | |
| US201662339944P | 2016-05-22 | 2016-05-22 | |
| US201662346348P | 2016-06-06 | 2016-06-06 | |
| US201662397832P | 2016-09-21 | 2016-09-21 | |
| US201662398422P | 2016-09-22 | 2016-09-22 | |
| US201662403664P | 2016-10-03 | 2016-10-03 | |
| US201662430547P | 2016-12-06 | 2016-12-06 | |
| US201762442948P | 2017-01-05 | 2017-01-05 | |
| PCT/US2017/021991 WO2017156513A1 (en) | 2016-03-11 | 2017-03-11 | Formulations and doses of pegylated uricase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318183A true IL318183A (en) | 2025-03-01 |
Family
ID=58464628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318183A IL318183A (en) | 2016-03-11 | 2017-03-11 | Formulations and doses of pegylated uricase |
| IL261700A IL261700A (en) | 2016-03-11 | 2018-09-12 | Formulations and dosages of oricase modified in polyethylene glycol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261700A IL261700A (en) | 2016-03-11 | 2018-09-12 | Formulations and dosages of oricase modified in polyethylene glycol |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20170258927A1 (OSRAM) |
| EP (2) | EP3426285B1 (OSRAM) |
| JP (3) | JP7417354B2 (OSRAM) |
| KR (2) | KR20220123332A (OSRAM) |
| CN (1) | CN109152819A (OSRAM) |
| AU (2) | AU2017230891B2 (OSRAM) |
| BR (1) | BR112018068249A2 (OSRAM) |
| CA (1) | CA3017365A1 (OSRAM) |
| DK (1) | DK3426285T3 (OSRAM) |
| ES (1) | ES2986077T3 (OSRAM) |
| FI (1) | FI3426285T3 (OSRAM) |
| HR (1) | HRP20241127T1 (OSRAM) |
| HU (1) | HUE068144T2 (OSRAM) |
| IL (2) | IL318183A (OSRAM) |
| LT (1) | LT3426285T (OSRAM) |
| MX (1) | MX2018011012A (OSRAM) |
| PL (1) | PL3426285T3 (OSRAM) |
| PT (1) | PT3426285T (OSRAM) |
| RS (1) | RS65941B1 (OSRAM) |
| SI (1) | SI3426285T1 (OSRAM) |
| WO (1) | WO2017156513A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ562292A (en) | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| US20130039954A1 (en) | 2011-07-29 | 2013-02-14 | Selecta Biosciences, Inc. | Control of antibody responses to synthetic nanocarriers |
| CN118370823A (zh) | 2013-05-03 | 2024-07-23 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
| WO2016037162A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| EP3538135A4 (en) | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| HUE072005T2 (hu) | 2017-03-11 | 2025-10-28 | Cartesian Therapeutics Inc | Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények |
| CN111373034A (zh) | 2017-07-07 | 2020-07-03 | 艾乐娜制药有限公司 | 重组尿酸酶 |
| CN109875988B (zh) * | 2018-09-13 | 2021-08-27 | 江西中医药大学 | 一种化合物dhnb缩氨基脲的合成及其在防治痛风与高尿酸血症的应用 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| CN114207440A (zh) * | 2019-06-04 | 2022-03-18 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| WO2021042055A1 (en) * | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
| US20210154324A1 (en) * | 2019-10-21 | 2021-05-27 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| JP2023501457A (ja) * | 2019-11-08 | 2023-01-18 | セレクタ バイオサイエンシーズ インコーポレーテッド | ペグ化ウリカーゼの処方物および用量 |
| KR102200329B1 (ko) * | 2019-11-11 | 2021-01-08 | 광주과학기술원 | 반감기 증가를 위한 치료용 단백질-지방산 접합체 및 이의 용도 |
| EP4588513A3 (en) * | 2020-08-10 | 2025-10-22 | Horizon Therapeutics USA, Inc. | Methods of treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| WO2025076412A1 (en) * | 2023-10-04 | 2025-04-10 | Gro Biosciences Inc. | Modified polypeptides and methods of making and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| CN1406140A (zh) | 2000-02-28 | 2003-03-26 | 吉倪塞思公司 | 纳米胶囊包封系统与方法 |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| KR101376715B1 (ko) | 2003-12-19 | 2014-03-27 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법 |
| EP1768692B8 (en) | 2004-07-01 | 2015-06-17 | Yale University | Targeted and high density drug loaded polymeric materials |
| EP2620157A3 (en) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| CN103501812A (zh) * | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| AU2014262164B2 (en) * | 2013-05-03 | 2020-02-27 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| CN118370823A (zh) * | 2013-05-03 | 2024-07-23 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
| ES2865375T3 (es) | 2014-11-05 | 2021-10-15 | Selecta Biosciences Inc | Métodos y composiciones relacionadas con nanovehículos sintéticos con rapamicina en un estado sobresaturado estable |
-
2017
- 2017-03-11 CA CA3017365A patent/CA3017365A1/en active Pending
- 2017-03-11 PT PT177152980T patent/PT3426285T/pt unknown
- 2017-03-11 RS RS20240946A patent/RS65941B1/sr unknown
- 2017-03-11 CN CN201780028609.1A patent/CN109152819A/zh active Pending
- 2017-03-11 HU HUE17715298A patent/HUE068144T2/hu unknown
- 2017-03-11 DK DK17715298.0T patent/DK3426285T3/da active
- 2017-03-11 ES ES17715298T patent/ES2986077T3/es active Active
- 2017-03-11 MX MX2018011012A patent/MX2018011012A/es unknown
- 2017-03-11 PL PL17715298.0T patent/PL3426285T3/pl unknown
- 2017-03-11 EP EP17715298.0A patent/EP3426285B1/en active Active
- 2017-03-11 FI FIEP17715298.0T patent/FI3426285T3/fi active
- 2017-03-11 KR KR1020227029367A patent/KR20220123332A/ko active Pending
- 2017-03-11 EP EP24177803.4A patent/EP4445955A3/en active Pending
- 2017-03-11 KR KR1020187029146A patent/KR20180120753A/ko not_active Ceased
- 2017-03-11 LT LTEPPCT/US2017/021991T patent/LT3426285T/lt unknown
- 2017-03-11 US US15/456,520 patent/US20170258927A1/en not_active Abandoned
- 2017-03-11 SI SI201731543T patent/SI3426285T1/sl unknown
- 2017-03-11 BR BR112018068249-7A patent/BR112018068249A2/pt unknown
- 2017-03-11 IL IL318183A patent/IL318183A/en unknown
- 2017-03-11 HR HRP20241127TT patent/HRP20241127T1/hr unknown
- 2017-03-11 AU AU2017230891A patent/AU2017230891B2/en active Active
- 2017-03-11 WO PCT/US2017/021991 patent/WO2017156513A1/en not_active Ceased
- 2017-03-11 JP JP2018548079A patent/JP7417354B2/ja active Active
-
2018
- 2018-09-12 IL IL261700A patent/IL261700A/en unknown
-
2022
- 2022-01-27 JP JP2022011177A patent/JP7547402B2/ja active Active
-
2024
- 2024-04-15 JP JP2024065367A patent/JP2024102099A/ja active Pending
- 2024-07-15 AU AU2024204851A patent/AU2024204851A1/en not_active Abandoned
- 2024-08-29 US US18/818,714 patent/US20250090451A1/en active Pending
- 2024-10-31 US US18/933,195 patent/US20250057756A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL318183A (en) | Formulations and doses of pegylated uricase | |
| JP2019507797A5 (OSRAM) | ||
| JP2022068180A5 (OSRAM) | ||
| JP2024102099A5 (OSRAM) | ||
| JP2020510687A5 (OSRAM) | ||
| JP2019206593A5 (OSRAM) | ||
| JP2010512384A5 (OSRAM) | ||
| CN114207440A (zh) | 聚乙二醇化尿酸酶的制剂和剂量 | |
| CN115190795A (zh) | 聚乙二醇化尿酸酶的制剂和剂量 | |
| JP2016512247A5 (OSRAM) | ||
| Koutroubakis | Recent advances in the management of distal ulcerative colitis | |
| Jurgens et al. | The use of conventional disease-modifying anti-rheumatic drugs in established RA | |
| Cohen et al. | SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study | |
| Samborski et al. | Intra‐articular treatment of arthritides and activated osteoarthritis with the 5‐HT3 receptor antagonist tropisetron. A double‐blind study compared with methylprednisolone | |
| US20180368458A1 (en) | Time release vitamins and minerals in edible oils | |
| JPWO2020247625A5 (OSRAM) | ||
| CN104000809A (zh) | 一种防治冠心病心绞痛的药物组合物及其应用 | |
| CN114642734A (zh) | 药物及siRNA共递送纳米复合物及其制备方法与应用 | |
| RU2015128915A (ru) | Составы лоразепама с замедленным высвобождением | |
| Schlesinger et al. | Uricases: reflections on recent developments in the management of challenging gout patients | |
| RU2021136782A (ru) | Композиции и дозы пегилированной уриказы | |
| JPWO2020047113A5 (OSRAM) | ||
| Maheu et al. | Effects of strontium ranelate on hand osteoarthritis. Analysis of data from the SEKOIA trial | |
| CN118161499A (zh) | 一种含有非布司他和叶酸或其衍生物的药物组合物 | |
| Coles et al. | Concomitant administration of methotrexate does not improve efficacy of intra-articular joint injections in patients with oligoarticular juvenile idiopathic arthritis |